Individualizing the Treatment of Type 2 Diabetes with a Focus on Cardiovascular Outcomes
Course expires: 10/01/2019
Emerging clinical evidence regarding the impact of hyperglycemia on cardiovascular outcomes warrants that physicians utilize a multifaceted approach to decrease cardiovascular risk in patients with type 2 diabetes mellitus. However, the increasing array of antidiabetic agents requires education about the effective use of combination therapies to enhance patient outcomes.
This educational activity will feature expert faculty discussing
- The effective use of therapeutic strategies in redefining the need to individualize treatment with a patient-first approach
- Assessing new as well as emerging clinical evidence to improve glycemic control, reducing cardiovascular risk.
Upon proper completion of this activity, participants should be better able to:
- Review the impact of antidiabetic medications in patients with multiple comorbidities such as hypertension, reduced renal function, obesity, and cardiovascular disease.
- Incorporate individualized treatment strategies for patients with type 2 diabetes and cardiovascular risk factors based on the latest clinical evidence.
- Apply clinical evidence on medications’ efficacy and safety when selecting monotherapy or combination therapy in patients with type 2 diabetes and cardiovascular risk factors.
This activity has been designed to address the educational needs of Endocrinologists and other health professionals who treat Type 2 Diabetes.
The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.